M.D. Anderson Cancer Center

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, M.D. Anderson Cancer Center sits in the top decile of US sponsors by registered trial count (#3 of 15,751 sponsors by registered trial count).

2,692 total trials 549 currently recruiting 1201 completed early-phase tilt top decile by trial count

M.D. Anderson Cancer Center: 2,692 sponsored US clinical trials, 549 recruiting.

M.D. Anderson Cancer Center sponsors 2,692 registered US clinical trials on ClinicalTrials.gov, 549 of them currently recruiting, and 1,201 completed. 124 of these trials are in Phase 3-4 (later-stage) and 1,719 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Hematopoietic and Lymphoid Cell Neoplasm, with 44 trials.

Top-decile sponsor footprint

M.D. Anderson Cancer Center ranks in the top decile of sponsors by registered trial count (#3 of 15,751 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Open and recent trials

2,692 total, page 26 of 54

COMPLETED NA

Flexible Intubation Scope With or Without Video Laryngoscope in Supporting Endotracheal Tube Placement in Patients With Head and Neck Cancer Before Surgery

NCT03757091
COMPLETED Phase 1

Gallium Ga 68-DOTATATE PET/CT in Predicting Tumor Growth in Patients With Meningiomas

NCT03953131
COMPLETED Early Phase 1

Personalized Vaccine in Treating Patients With Smoldering Multiple Myeloma

NCT03631043
COMPLETED Early Phase 1

Patient-Derived Xenografts in Personalizing Treatment for Patients With Relapsed/Refractory Mantle Cell Lymphoma

NCT03219047
TERMINATED Phase 1

Milademetan Tosylate and Low-Dose Cytarabine With or Without Venetoclax in Treating Participants With Recurrent or Refractory Acute Myeloid Leukemia

NCT03634228
COMPLETED NA

GRAvity- Versus Wall Suction-drIven Large Volume Thoracentesis: a RAndomized Controlled Study (GRAWITAS Study)

NCT05131945
COMPLETED NA

Quit4Health Intervention in Supporting Smoking Cessation and Preventing Smoking Initiation in Young Adults

NCT04009590
TERMINATED NA

Effectiveness of an Online Intervention Targeting Cancer-related Fatigue

NCT03809130
COMPLETED NA

18F-FDG PET-MRI for Planning and Follow-Up of Patients With Spine Tumors Treated With Spine Stereotactic Radiosurgery

NCT05174026
TERMINATED Early Phase 1

Levorphanol as a Second Line Opioid in Reducing Pain in Patients With Cancer

NCT03579446
TERMINATED Phase 2

DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers

NCT03439085
COMPLETED Phase 2

Linear Energy Transfer (LET)-Optimized Intensity Modulated Proton Therapy (IMPT) as a Component of Definitive Chemoradiation for Newly Diagnosed Squamous Cell Carcinoma of the Anal Canal: a Feasibility Trial

NCT03690921
TERMINATED Phase 2

Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma

NCT03610490
COMPLETED Phase 1

Nivolumab and Ipilimumab After Donor Stem Cell Transplant in Treating Patients With High Risk Refractory or Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome

NCT03600155
COMPLETED NA

Meditative Slow Breathing or Isha Kriya Meditation in Improving Cancer-Related Symptoms in Hospitalized Participants With Cancer

NCT03445572
COMPLETED Phase 1

Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis

NCT03508570
COMPLETED NA

FDG PET-MRI for the Diagnosis of Spinal Cord Lesions

NCT04219969
TERMINATED NA

Bronchoscopic Laser Ablation of Peripheral Lung Tumors

NCT03707925
COMPLETED Phase 1

Modified T Cells, Chemotherapy, and Aldesleukin With or Without LV305 and CMB305 in Treating Participants With Advanced or Recurrent Sarcoma

NCT03450122
COMPLETED Phase 1

T-Cell Infusion, Aldesleukin, and Utomilumab in Treating Patients With Recurrent Ovarian Cancer

NCT03318900
TERMINATED Phase 1

Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors

NCT03420963
COMPLETED

Survey of Post-Acute Inpatient Rehabilitation Safety Concerns in Participants With Cancer

NCT03656224
COMPLETED NA

DECT in Imaging Patients With Solid Organ Cancer With Intracranial Metastasis

NCT03685539
TERMINATED Phase 1

ADCT-602 in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia

NCT03698552
COMPLETED Phase 1

Hydroxychloroquine, Palbociclib, and Letrozole Before Surgery in Treating Patients With Estrogen Receptor Positive, HER2 Negative Breast Cancer

NCT03774472
COMPLETED Phase 1

Tinostamustine With or Without Radiation Therapy in Treating Patients With Newly Diagnosed MGMT-Unmethylated Glioblastoma

NCT03452930
COMPLETED NA

Tailored Smoking Cessation Intervention in Promoting Sexual and Gender Minority Smokers to Quit Smoking

NCT03669120
COMPLETED Phase 1

M7824 in Treating Patients With Stage II-III HER2 Positive Breast Cancer

NCT03620201
COMPLETED Phase 4

Dual Time Point FDG PET/MRI Scan in Improving the Imaging Cancer Patients With Brain Metastases

NCT05054998
COMPLETED

Chronic Non-Malignant Pain in Cancer Patients at a Supportive Care Clinic

NCT03043378
COMPLETED Phase 1

Stereotactic Body Radiation Therapy, Tremelimumab and Durvalumab in Treating Participants With Recurrent or Metastatic Cervical, Vaginal, or Vulvar Cancers

NCT03452332
COMPLETED Phase 1

STAT3 Inhibitor WP1066 in Treating Patients With Recurrent Malignant Glioma or Progressive Metastatic Melanoma in the Brain

NCT01904123
TERMINATED Phase 1

Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia

NCT03576547
COMPLETED NA

Barriers Affecting Physical Activity

NCT03573375
COMPLETED NA

Standard and Delayed FDG PET/CT After Chemoradiation Therapy in Assessing Patients With Metastatic Head and Neck Squamous Cell Cancer

NCT03575949
TERMINATED Phase 1

M7824 and Eribulin Mesylate in Treating Patients With Metastatic Triple Negative Breast Cancer

NCT03579472
COMPLETED Early Phase 1

Daratumumab in Treating Patients with Muscle Invasive Bladder Cancer or Metastatic Kidney Cancer

NCT03473730
COMPLETED Phase 2

Ibrutinib as Early Therapy in Chronic Lymphocytic Leukemia (CLL)

NCT03207555
TERMINATED Phase 2

Levocarnitine and Vitamin B Complex in Treating PEG-Asparaginase or Inotuzumab Ozogamicin-Induced Hyperbilirubinemia in Patients With Acute Lymphoblastic Leukemia

NCT03564678
COMPLETED Phase 2

Comparative Study To Determine The Efficacy, Safety, And Tolerability Of Ceftolozane-Tazobactam

NCT03485950
COMPLETED Phase 1

Radiation Therapy and M7824 in Treating Patients With Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer

NCT03524170
COMPLETED

Radial-Probe Endobronchial Ultrasound in Detecting Atelectasis in Patients Undergoing Peripheral Bronchoscopy

NCT03523689
TERMINATED Phase 2

Low-Intensity Chemotherapy and Blinatumomab in Treating Patients With Philadelphia Chromosome Negative Relapsed or Refractory Acute Lymphoblastic Leukemia

NCT03518112
COMPLETED NA

Cycling in Preventing Colorectal Cancer in Participants With Lynch Syndrome

NCT03495674
TERMINATED Phase 2

Utomilumab and ISA101b Vaccination in Patients With HPV-16-Positive Incurable Oropharyngeal Cancer

NCT03258008
TERMINATED Phase 2

Combination Chemotherapy and Inotuzumab Ozogamicin in Treating Patients With B Acute Lymphoblastic Leukemia

NCT03488225
COMPLETED Phase 2

Study of Durvalumab (MEDI4736) (Anti-PD-L1) and Trametinib (MEKi) in MSS Metastatic Colon Cancer

NCT03428126
COMPLETED Phase 1

Sapanisertib, Carboplatin, and Paclitaxel in Treating Patients With Recurrent or Refractory Malignant Solid Tumors

NCT03430882
COMPLETED Phase 1

Sapanisertib and Metformin in Treating Patients With Advanced or Metastatic Relapsed or Refractory Cancers

NCT03017833
COMPLETED Phase 1

M7824 in Patients With Metastatic Colorectal Cancer or With Advanced Solid Tumors With Microsatellite Instability

NCT03436563
← Previous Page 26 of 54 Next →

Phase Distribution

PhaseTrial count
Phase 1 748
Phase 2 971
Phase 3 96
Phase 4 28

Therapeutic Areas

Hematopoietic and Lymphoid Cell Neoplasm 44
Malignant Solid Neoplasm 42
Breast Cancer 41
Acute Myeloid Leukemia 38
Leukemia 37
Myelodysplastic Syndrome 33
Lymphoma 32
Cancer 31
Recurrent Acute Myeloid Leukemia 25
Lung Cancer 23

What is open in the M.D. Anderson Cancer Center pipeline

549 recruiting of 2,692 indexed (20% open); 1,201 completed (45%).

Phase mix: 124 late (III/IV) vs 1,719 early (I/II) (early-phase heavy).

Top condition: Hematopoietic and Lymphoid Cell Neoplasm (44 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Related

Compare saved trials side-by-side

Read our methodology - how this data is sourced, computed, and verified.
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.